Canada markets open in 3 hours 5 minutes
  • S&P/TSX

    21,077.35
    -85.30 (-0.40%)
     
  • S&P 500

    4,701.21
    +14.46 (+0.31%)
     
  • DOW

    35,754.75
    +35.32 (+0.10%)
     
  • CAD/USD

    0.7887
    -0.0019 (-0.24%)
     
  • CRUDE OIL

    71.80
    -0.56 (-0.77%)
     
  • BTC-CAD

    62,460.21
    -388.38 (-0.62%)
     
  • CMC Crypto 200

    1,285.95
    -19.16 (-1.47%)
     
  • GOLD FUTURES

    1,784.00
    -1.50 (-0.08%)
     
  • RUSSELL 2000

    2,271.71
    +17.92 (+0.80%)
     
  • 10-Yr Bond

    1.5090
    0.0000 (0.00%)
     
  • NASDAQ futures

    16,309.50
    -82.75 (-0.50%)
     
  • VOLATILITY

    20.47
    -1.42 (-6.49%)
     
  • FTSE

    7,334.49
    -2.56 (-0.03%)
     
  • NIKKEI 225

    28,725.47
    -135.15 (-0.47%)
     
  • CAD/EUR

    0.6965
    -0.0002 (-0.03%)
     

RxSight to Report Third Quarter 2021 Financial Results on November 10, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

ALISO VIEJO, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced that it will report financial results for the third quarter of 2021 after the market close on Wednesday, November 10, 2021. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.rxsight.com, on the Investors page in the News and Events section. The call will also be available by dialing 844-602-7038 (U.S.) or 916-637-9714 (International) five to ten minutes prior to the start time, using conference ID: 1239025.

About RxSight, Inc.
RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens (LAL®), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The LAL now features ActivShield™ technology, a revolutionary UV protection layer built into the lens. Additional information about RxSight® can be found at www.rxsight.com.

Investor Relations Contact:
Philip Taylor
Gilmartin Group
415.937.5406
IR@rxsight.com

Company contact:
Roy Freeman
Sr. Director, Marketing
rfreeman@rxsight.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting